Major Depressive Disorder

Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.

A clinical-stage biopharmaceutical company and a global contract research organization have partnered to support the ongoing development of investigational, psychedelic therapeutics to treat a range of psychiatric disorders.

monotherapy for the treatment of major depressive disorder, is set to enter a phase 3 clinical program, with a new drug application expected in 2025, according to a press release.

BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.

Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.

Esketamine is an effective and well-tolerated treatment option for adolescents with major depressive disorder and suicidal ideation, according to a study published in the Journal of the American Academy of Child & Adolescent Psychiatry.

A biopharmaceutical company has announced positive safety and tolerability data from a United States-based phase 1 clinical trial of its investigational rapid-onset pherine nasal spray to treat major depressive disorder.

MIAMI BEACH, Fla. — For adults with major depressive disorder, treatment with zuranolone was linked to improvements in self-reported depressive symptoms, longer repeat treatment intervals and was generally well-tolerated.

MIAMI BEACH, Fla. — Adjunctive treatment with aticaprant for those with major depressive disorder and history of antidepressant failure resulted in greater symptom improvement compared with placebo after 6 weeks, a presenter said.

SAN FRANCISCO — For patients with treatment-resistant major depressive disorder, deep transcranial magnetic stimulation significantly improved symptoms and quality of life compared with sham, according to a poster presented here.